p95HER2 Antibody–drug conjugates (ADC)

This presentation introduces a promising in vitro data package centered around a novel Antibody-Drug Conjugate (ADC) developed with the unique Oslo2 antibody. Designed to meet the pressing demands of treating metastatic HER2 positive cancers, this ADC targets the p95HER2 protein—a specific marker not currently addressed by existing treatments. The breakthrough lies in the creation of a first-in-class therapy that is highly tumor-specific, thereby minimizing toxicity to normal tissues. This novel approach holds the potential to provide a safe and effective solution for patients resistant to current therapies, offering a much-needed alternative for those with advanced stages of breast, colorectal, lung, ovarian, and endometrial cancers. Importantly, this ADC complements a pre-clinical p95HER2 CAR T technology also in development within our pipeline. While both target the same protein, they serve distinct patient groups. ADC therapy is designed for broader accessibility and earlier-line treatments, whereas CAR T, potent yet costly, is reserved as a last-resort option requiring specialized infrastructure. Feedback from recent business development meetings has shown robust interest from pharmaceutical companies and venture capitalists, emphasizing the ADC’s commercial attractiveness and its strategic position as a preferred therapeutic implementation over CAR T options. In conclusion, this project aims to harness the unique capabilities of the p95HER2-directed ADC to address a significant unmet medical need, providing patients with metastatic HER2 positive cancers a new hope.

The development of the novel Antibody-Drug Conjugate (ADC) targeting p95HER2 protein has yielded promising in vitro results, showcasing its tumor-specific efficacy and reduced toxicity compared to existing treatments. Actual outcomes include the identification of a safe therapeutic approach for metastatic HER2 positive cancers, addressing critical gaps in treating these advanced stages. Potential impacts are substantial; the ADC represents a scientific advancement that could revolutionize cancer treatment, offering new hope to patients and positioning the therapy as a commercially viable alternative, attracting interest and investment from pharmaceutical companies and venture capitalists. As this project progresses, it may significantly improve patient outcomes and expand accessible cancer treatment options globally.